All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit Know AML.

The AML Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your AML Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The AML Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the AML Hub cannot guarantee the accuracy of translated content. The AML Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

MPN Hub

MPN Hub

Multiple Myeloma

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact
TypesTherapeuticsCongressesTrialsExpert OpinionsDRUG UPDATES
2018-12-11T02:09:26.000Z

Amir Fathi | ASH 2018 | Alisertib in combination with induction chemotherapy in high-risk patients with AML

By Cynthia Umukoro
Featured
Amir Fathi
Dec 11, 2018
Share:

Bookmark this article

At the 2018 American Society of Hematology meeting, Amir Fathi from Massachusetts General Hospital, Boston, US, discusses the results from a phase II study of alisertib, an aurora a kinase inhibitor, in combination with induction chemotherapy in high-risk, untreated patients with acute myeloid leukemia (AML). 

Alisertib combined with conventional induction, is efficacious and demonstrates a promising rate of remission and survival among patients with previously untreated high-risk AML.

Alisertib in combination with induction chemotherapy in high-risk patients with AML

More about...
AlisertibASH 2018DiseaseSecondaryTherapy-related

Your opinion matters

Do you intend to implement next-generation sequencing for measurable residual disease monitoring in MDS patients?
1 vote - 4 days left ...

Related articles

Add bookmark

Optimizing the dose of venetoclax with less intensive therapies for elderly patients with newly diagnosed AML

Suresh Agarwal conducted a study to characterize the exposure-efficacy and exposure-safety relationships in order to identify the optimal...

Jul 18, 2019
Add bookmark

Optimizing the dose of venetoclax with less intensive therapies for elderly patients with newly diagnosed AML

Suresh Agarwal conducted a study to characterize the exposure-efficacy and exposure-safety...

Jul 18, 2019
Add bookmark

ASH 2018 | Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia – CAVEAT study

Venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable and is associated with a high CR/CRi in patients...

Dec 12, 2018
Add bookmark

ASH 2018 | Venetoclax in combination with chemotherapy in elderly patients with acute myeloid leukemia – CAVEAT study

Venetoclax up to 600mg in combination with 5+2 induction chemotherapy is tolerable...

Dec 12, 2018

Newsletter

Subscribe to get the best content related to AML delivered to your inbox